Organogenesis (NASDAQ:ORGO) Trading Up 6.2% After Analyst Upgrade

Organogenesis (NASDAQ:ORGO) shares shot up 6.2% during mid-day trading on Friday after BTIG Research raised their price target on the stock from $7.00 to $9.00. BTIG Research currently has a buy rating on the stock. Organogenesis traded as high as $5.48 and last traded at $5.4350. 215,220 shares changed hands during trading, a decline of 85% from the average session volume of 1,433,693 shares. The stock had previously closed at $5.12.

A number of other research firms have also issued reports on ORGO. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Cantor Fitzgerald increased their price objective on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a report on Thursday, November 13th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Organogenesis has an average rating of “Hold” and an average target price of $8.00.

Institutional Trading of Organogenesis

A number of institutional investors have recently bought and sold shares of the business. Trexquant Investment LP purchased a new position in shares of Organogenesis in the 1st quarter valued at about $516,000. Assenagon Asset Management S.A. boosted its holdings in Organogenesis by 748.1% in the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock valued at $10,460,000 after purchasing an additional 2,520,941 shares in the last quarter. Cerity Partners LLC increased its stake in Organogenesis by 48.2% in the first quarter. Cerity Partners LLC now owns 74,880 shares of the company’s stock valued at $323,000 after purchasing an additional 24,362 shares during the last quarter. Vanguard Group Inc. increased its stake in Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after purchasing an additional 841,618 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Organogenesis by 45.3% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 667,529 shares of the company’s stock worth $2,884,000 after purchasing an additional 208,038 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Stock Up 9.2%

The firm’s 50-day moving average price is $4.62 and its two-hundred day moving average price is $4.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The firm has a market cap of $709.43 million, a PE ratio of -46.58 and a beta of 1.68.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The firm had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.